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a Data generated by commercial suppliers. b Data generated by Heptares. c Mass spectrometry was performed at Heptares using a Micromass ZQ spectrometer with electrospray ionisation conditions.
Chemical Synthesis
Hit compounds 1-10 and follow-up compounds 11-14 were provided by Chembridge, Interchim, Asinex, BioFocus or Interbioscreen. The compounds were supplied with HPLC purities >95%, as determined by the vendors, or Heptares, as delineated in Table S1 .
Chemical synthesis and analysis of compounds 15 and 16 were carried out at Oxygen Healthcare. Unless otherwise stated, all reagents were commercially available and were used as supplied, without further purification. 1 1.5 mL/min. LCMS purities were measured by diode array detection (AUC) at the specified retention time and were determined to be ≥95% in all cases.
Typical Procedure for Suzuki Couplings
A aryl halide derivative (1 eq) and an arylboronic acid derivative (1 eq) were mixed in 1,4-dioxane (10-20 mL per gram of chlorotriazine), and treated with an aqueous solution of Na 2 CO 3 or K 2 CO 3 (2 eq, 10% water v/v). The mixture was then de-gassed, treated with tetrakis triphenylphosphine palladium (5 mol%) at room temperature for 5 mintues, and then heated either conventionally at 70-100 o C, or in a microwave reactor, until the disappearance of starting materials was observed by TLC. The reaction was then cooled to room temperature and quenched with water (1 volume). The target compounds were isolated by extracting the mixture with an organic solvent (3 successive volumes), drying the combined organics over anhydrous sodium sulfate, then removing the solvent in vacuo and purifying the product by flash chromatography. 
Preparation of {3-[4-amino-6-(2-phenol)-1,3,5-triazin-2-yl]phenyl}(4-methylpiperazin-1-yl)methanone
A three-necked, round-bottomed flask was charged with toluene (30 mL), 1,3-dibromo benzene (8.2 g, 34.70 mmol) and 4-methylpiperidine (4.9 g, 34.70 mmol). The reaction mixture was stirred for 10 min at RT. BINAP (217 mg, 0.35 mmol) and Pd 2 (dba) (106 mg, 0.115 mmol) were then added, and the reaction mixture was stirred for a further 10 min at RT. Following the addition of DBU (4.33 g, 28.5 mmol), the mixture was heated to 60 °C, treated with NaO t Bu (5.0 g, 52.5 mmol) and refluxed overnight. After The protein preparation and docking experiments were done within the Schrodinger Maestro package. The grid generation necessary for docking was done within Glide. The residues highlighted in SDM experiments (in-house and external) were used to further define the cavity of the grid. However, no constraints were added in the grid generation to ensure subsequent dockings were not biased in any way. As standard, up to 3 poses per molecular structure were stored for analysis as detailed above. For some compound subsets, Glide XP docking was carried out on the ligands with 10 poses per ligand being stored. A selection of a total of 632 commercial vendor compounds (CAP) and 52 SoftFocus compounds, combined from all screens after further filtering by molecular properties and visual inspection as described in the main text, were initially selected for sourcing and a set of 372 virtual hits was finally prioritised for purchasing, following manual inspection and subsequent triaging by medicinal chemistry of the most promising docking solutions. The overall virtual process is shown schematically in figure S2 , with details of the workflows S8 used for the docking and analysis shown in figures S3 and S4. 232 compounds were finally screened after logistical criteria (cost and availability etc).
The Table (S1) below indicates the closest published Adenosine A 2A receptor antagonist in terms of Tanimoto similarity, and calculated logBB values (blood-brain barrier penetration). The similarity analysis was performed by generating a database of published A 2A antagonists from the publically available ChEMBL data source (https://www.ebi.ac.uk/chembl/) and for each hit molecule querying to identify the most similar molecules reported. The searches were carried out using Pipeline Pilot 8.5
(http://accelrys.com/products/pipeline-pilot/) using SciTegic extended-connectivity functional class fingerprints with a maximum bond distance of 4 from the central atom (FCFP_4). In each case the nearest similar molecule has very low similarity (~0.3 or less) indicating that the virtual screen had been successful in identifying distinct chemotypes as antagonists of the protein target. The logBB prediction was performed using two methods, the first value using the method of Clark 11 (polar surface area and clogP) and the second using StarDrop. Predicted values were not used during the filtering process, the variability between the methods being evident, but taking for example the first method, all values are > -1 and an analysis of 64 CNS drugs by this method showed 41% to be in the -1 to 0 range, with 15% actually between -1.5 to -1. Figure S2 . Overall workflow used for the A 2A virtual screening using the two different homology models and compound sets created from commercially available vendor compounds (CAP) and
S9
Biofocus DPI SoftFocus™ compounds. Prior to docking, the tautomers and ionisation states were enumerated using either Pipeline Pilot (model 1 work) or Ligprep (model 2 work). The numbers refer to the datasets after compounds with general unwanted chemical functionality were removed but before this enumeration, so represent the numbers of different compounds screened; the final medicinal chemist check was however more stringent on unwanted chemical functionality. More compounds were chosen based on the Model 2 work than Model 1 (of the 632 CAP compounds selected, 414 were selected from the Model 2 work) as more experimental SDM data was used in the screening and analysis process; an improved ligand preparation protocol was also used.
Clustering was done using Pipeline Pilot extended connectivity fingerprints. 
